




已阅读5页,还剩69页未读, 继续免费阅读
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
高度脂溶性钙离子拮抗剂 在高血压、动脉硬化中的应用 北京大学人民医院 孙宁玲,高血压的进展,2000全球死亡率: 高血压对其他危险因素的影响,高死亡率, 发展中地区,低死亡率 发展中地区,发达地区,高血压 (BP),吸烟,高胆固醇,低体重,性别为男性,高体重指数,少动生活方式,饮酒,室内环境污染,缺铁,0,1000,2000,3000,4000,5000,6000,7000,8000,死亡率分布 (In thousands; total 55,861,000),Adapted from Ezzati et al, Lancet, 2002.,高血压患者心血管事件危险性增高,弗明翰心脏研究 - 高血压与正常血压的心血管事件危险性 (患者年龄35-64岁,随 访36年),Risk Ratio 2.0 2.2 3.8 2.6 2.0 3.7 4.0 3.0 Excess Risk 22.7 11.8 9.1 3.8 4.9 5.3 10.4 4.2,冠脉疾病,中风,外周血管疾病,心衰,Biennial Age-Adjusted Rate per 1000,Kannel WB JAMA 1996;275(24):1571-1576.,高血压及动脉硬化 参与 心血管事件的发生,高血压与动脉硬化是相联的,a,Hypertension,Other factors - hypercholesterolaemia - glucose intolerance etc.,Atherosclerosis,Coagulation factors,Clinical events of CHD - angina - infarction - sudden death,(very late stage),Relationship between hypertension, atherosclerosis and cardiovascular events,a,Hypertension,出血性卒中,Atherosclerosis,缺血性 卒中,其他致 动脉硬化因素,血栓,心绞痛/心肌梗死,a,高血压是动脉硬化的启动因素,动脉粥样硬化的进展过程与高血压有关,LDL Oxidised LDL,动脉壁损伤 细胞粘附于内皮表面,内皮功能失调 使内皮渗透性增加,生长因子 eg. PDGF, FGF, TGF-b,平滑肌细胞增殖,高血压,高血压,高血压,高血压怎样导致动脉硬化: haemodynamic factors,a,Internal Carotid,External Carotid,Flow Divider,Common Carotid Artery,Main steps in the atherosclerotic process (atherogenesis),a,平滑肌细胞增殖.,迁移至内皮下,高血压,高血压怎样导致动脉硬化: mechanical factors,a,内皮损伤,High BP,Lipids/free radicals,渗透性增加,内皮的收缩因子(内皮素)占优,Main steps in the atherosclerotic process (atherogenesis),a,(Per-) Oxidation,吞噬细胞增殖,Esterification,(脂化作用),炎症与动脉粥样硬化形成及演变,正常 黏附 侵润 剥落,内皮细胞,平滑肌细胞,CAMs,基质,泡沫细胞,T淋巴细胞,激活的巨核细胞,组织因子 栓塞 MMPs 基质降解,高血压,L-NMMA = NG monomethyl L-arginine monoacetate. John and Schmieder. J Hypertens. 2000;18:363-374.,Gene expression,G,Endothelial Cell,L-Arginine,L-NMMA,eNOS,Ca2+ calmodulin,Acetylcholine,Substance P,Bradykinin,2-agonists,pathway,L-Arginine,NO,Soluble guanylate cyclase,cGMP,Endothelium-dependent vasodilation,Smooth Muscle Cell,Endothelium-Dependent Vasodilation: L-ArginineNitric Oxide Pathway,Endothelial injury,Removal of endothelial cells,Cytokines and growth factors,Cell adhesion molecules,Endothelial repair,Incorporation of endothelial progenitor cells,Cytokines and growth factors,Cell adhesion molecules,Adapted from Omoigui and Dzau. J Vasc Med Biol. 1991;3:382-391.,高血压是内皮功能 不良的重要原因 并导致血管组织 结构的病变,Abnormal Endothelium,Vasocon- striction,Platelet/ leukocyte adhesion,SMC migration and growth,Lipid deposition Clearance,高血压,糖尿病,Dysfunction,血脂紊乱,既往研究发现: 积极降脂治疗可以改善内皮 功能,降低预后事件,Effects of Lipid-Lowering Therapy on Endothelial Function in CHD Patients,Treasure et al. N Engl J Med. 1995;332:481-487.,Change in Diameter (%),30,20,10,0,-10,-20,-30,-40,-50,Initial,Follow-up,Placebo Group,Initial,Follow-up,Lovastatin Group,Dilation,Constriction,Acetylcholine Challenge,Effect of Aggressive Lipid Lowering on Carotid IMT in Heterozygous Familial Hypercholesterolemia: ASAP,Smilde et al. Lancet. 2001;357:577-581.,Change in IMT (mm),0.09,0.07,0.05,0.03,0.01,-0.01,-0.03,-0.05,-0.07,-0.09,0,1,2,Atorvastatin 80 mg (n=160),Years,Baseline LDL,8.33 mmol/L,Overview of Statin Trials,AF/TexCAPS 6605 -24%,4S 4444 -35%,LIPID 9014 -25%,CARE 4159 -28%,WOS 6595 -20%,Trial N LDL,% Reduction Major Coronary Events,Secondary,Primary,*P.001; P=.002 LaRosa et al. JAMA. 1999;282:2340-2346.,-38*,-25*,-25,-31*,-38*,结 论,积极的降脂治疗可以改善内皮功能 积极的降脂治疗可以改善动脉硬化及中间终点 积极降脂治疗可以改善预后终点,降压治疗是否可以改善预后? 降压治疗是否有改善内皮功能的作用? 什么样降压药物具有较好的抗动脉硬化效果?,问题的提出:,Reduction of events with antihypertensive therapy,a,a,20-25%,35-45%,Antihypertensive therapy,CHF,Stroke,MI,-20,-0,-40,-60,50%,2003 JNC7,钙离子在高血压及动脉硬化中的作用,a,a,Ca,+,Calciumions,1)内皮细胞(内皮素) 2) 血管平滑肌细胞 3) 巨噬/泡沫细胞 4) LDL/胆固醇代谢,钙离子拮抗剂是否能过阻断这些过程?,降压治疗(CCB)是否可以改善预后 降压治疗(CCB)是否有改善内皮功能的作用? 什么样降压药物具有较好的抗动脉硬化效果?,回答提出的问题,CCBs 在动脉硬化中的临床试验,Jukema J, et al. Arterioscler Thromb Vasc Biol 1996;16:42530. Lichtlen P, et al. Lancet 1990;335:110913. Pitt B, et al. Circulation 2000;102:150310.,结果已经发表在11月8日的 Lancet 2003,362:1527-35. 荟萃 29个随机试验 162,341例患者 700,000余次的病人年,降压治疗试验协作研究组 (ABPL)第二轮分析,ABPL 试验(血压的差异与事件的关系) 活性药物 vs plac,mmHg 差异 ACEI / plac ( -5 / -2 ) CCB / plac ( - 8 / - 4 ),R R R R 总死亡率 0.80 0.89 CVD死亡 0.80 0.78 CVD事件 0.72 0.82 脑卒中 0.72 0.62 冠心病 0.80 0.78 心力衰竭 0.82 1.21,ABPL 试验(血压的差异与事件的关系) 活性药物 vs 活性药物,mmHg 差异 ACEI CCB ACEI D / BB (+ / 0 ) D/BB (+1/ 0 ) CCB (+1 / +1 ),R R R R R R 总死亡率 1.00 0.99 1.04 CVD死亡 1.03 1.05 1.03 CVD事件 1.02 1.04 0.97 脑卒中 1.09 0.93 1.12 冠心病 0.98 1.01 0.96 心力衰竭 1.07 1.33 0.82,卒 中 不同活性药的比较,随机治疗,ACEI vs D/BB CA vs D/BB ACEI vs CA,试验数,6 9 6,病例数,47449 68467 25767,(mmHg),0/2 0/0 1/1,0.5 1.0 2.0,RR (95% CI),1.09(1.00, 1.18 0.93(0.86, 1.01 1.12(1.01, 1.25,Relative Risk,前者更好,后者更好,第二轮分析,ABPL,降压治疗(CCB)是否可以改善预后? 降压治疗(CCB)能够改善内皮功能 什么样降压药物具有较好的抗动脉硬化效果?,回答提出的问题,Circulating endothelial progenitor cells are derived from bone marrow,EPC: endothelial progenitor cell,EPC,Smooth muscle,Endothelium,Coronary artery,Bone marrow,EPC migration,EPC,Bone marrow,EPC incorporation,EPC: endothelial progenitor cell,心血管危险因素是与内皮原细胞数量的减少及不同有关,Endothelial progenitor cells (colony-forming units),5,0,5,10,15,Framingham risk score,0,20,40,60,30,50,70,10,20,p=0.001, r= 0.47,Hill J et al. N Engl J Med 2003,内皮功能改善与内皮源性细胞数量加有关,Endothelial progenitor cells (colony-forming units),0,2,4,6,8,Change in brachial reactivity (%),0,20,40,60,30,50,70,10,16,10,12,14,Hill J et al. N Engl J Med 2003,p=0.001, r= 0.59,EPC: endothelial progenitor cell,TREND: Endothelial Function and ACE Inhibition,*P.0003 for quinapril vs placebo. Mancini et al. Circulation. 1996;94:258-265.,P=.002 overall,Net Change (%) in Target Segment Response After 6 Months,Acetylcholine Dose (mol/L),10-6,10-4,*,Placebo,Quinapril,*,NO Production From Human Coronary Microvessels: Amlodipine and Ramiprilat,Zhang et al. Am J Cardiol. 1999;84:27L-33L.,Change in Nitrite (pmol/mg),Concentration (log),Amlodipine,*,*,*,*,*,*,*,Ramiprilat,*P.01 vs control,Brovkovych V et al. Hypertension 2001,Nifedipine preserves NO concentration stimulates NO release,Electrochemical sensor,0.01 0.1 1 10 100 1,000,240,120,40,0,80,200,160,NO release (nmol/L),Nifedipine (nmol/L),Loke et al. Hypertension. 1999;34:563-567; Zhang et al. J Pharmacol Exp Ther. 1999;288:742-751; Laufs et al. Circulation. 1998;97:1129-1135.,Postulated Effects of Different Agents on Endothelial Cell NO Production,Endothelial Cell,Statins,Kinins,Inactive peptides,CCB,eNOS,NO2,ACE,BK2,eNOS mRNA,ACEI,不同药物对内皮功能不良的治疗作用,ACE-Is,ARBs,CCBs,动脉,coronary,+,+,no data,peripheral,+,+,皮下微循环,+,+,+,肌性微循环,acetylcholine, metacholine,bradykinin,+,+,+,no data,ACE-I: angiotension-converting enzyme inhibitor, ARB: angiotensin II receptor blocker, CCB: calcium channel blocker,降压治疗(CCB)是否可以改善预后? 降压治疗(CCB)是否有改善内皮功能的作用? CCB具有较好的抗动脉硬化效果,回答提出的问题,ESC/ESH建议 分析心血管事件终点 既要看终末终点又要分析中间终点(替代终点),危险因素阶段,靶器官损害阶段,临床疾病阶段,终末疾病阶段,高血压 糖尿病 其它危险因素,颈动脉中内膜增厚 冠状动脉病变 血管内皮功能紊乱 左室肥厚 蛋白尿,心绞痛 心肌梗塞 脑卒中 肾脏损害,心力衰竭 肾功能衰竭 卒中后功能障碍 死亡,中间终点,逆转中间终点的目的是减少终末终点发生,心肌梗塞或中风与颈动脉厚度的关系,内膜-中层厚度的五分位数 (combined measure of max CCA and ICA),每1000名病人 出现心梗或中风的比率-年,13.6,18.4,22.2,40.9,New England Journal of Medicine, 1999;340:14-22,7.8,SECURE: Progression Slope of Mean Maximum IMT,Progression Mean Max IMT Slope (mm/y),0.022,0.018,Placebo (n=227),Ramipril 2.5 mg/d (n=232),0.014,Ramipril 10 mg/d (n=234),37% Relative Reduction P=.028 vs Plac,Effect of Ramipril Was Significant After Adjustment for BP and Hx Hypertension,Lonn et al. Circulation. 2001;103:919-925.,PREVENT:氨氯地平 显著延缓 颈动脉粥样硬化,内膜中层厚度变化,(mm),氨氯地平 安慰剂, 0.033, 0.013,Pitt et al. Circulation. 2000.,P=0.007,INSIGHT impact on intima-media thickness,Simon A, et al. Circulation 2001;103:294954.,Follow-up (years),Change from baseline in carotid artery IMT (mm),Nifedipine GITS,0.04 0.03 0.02 0.01 0 0.01,Co-amilozide,Progression,Regression,p=0.007,p=0.001,p=0.006,Baseline 2 3 4,Verapamil in Hypertension and Atherosclerosis Study (VHAS),Correlation of rate of change in mean maximum intima-media thickness (Mmax) and initial Mmax,Modified from Zanchetti A, et al. J Hypertens 1998;16:166776.,0.06 0.04 0.02 0 0.02 0.04 0.06 0.08 0.10 0.12,Rate of Mmax change (mm/year),y = 0.037x + 0.051,y = 0.082x + 0.086,Verapamil,Chlorthalidone,0.5 1.0 1.5 2.0,Initial Mmax (mm),拉西地平与阿替洛尔比较 主要终点结果 (每年CBMmax 的进展),0.0146,0.0145,0.0057,0.0087,0,0.005,0.01,0.015,0.02,0.025,PP,PP2,人群,mm,阿替洛尔,拉西地平,-61%,-40%,p=0,0010,p=0,0073,Circulation.2002;19:2422-2427,ELSA研究,拉西地平和细胞膜和钙通道的相互作用,High lipophilicity,Extracellular,Lacidipine Ca2+,Intracellular,slow dissociation,accumulation within lipid bilayer,long duration of action,INTERACTION OF LACIDIPINE WITH THE DIHYDROPYRIDINE RECEPTORS,Lacidipine inhibits the development of atherosclerosis,LDL Oxidised LDL,动脉壁损伤后细胞粘附于内皮表面,拉西地平减少内皮功能失常和渗透性增加,拉西地平减少平滑肌细胞增殖,拉西地平减少 LDL的氧化,Growth factors eg. PDGF, FGF, TGF-b,The effect of lacidipine on endothelium-dependent vasodilatation in hypertensives,700,600,500,400,300,200,100,0,Bradykinin,Acetylcholine,*,*,Normotensives Hypertensives Lacidipine-treated hypertensives,前壁血流 增加(%),* p 0.05 * p 0.01 compared to baseline,Ghiadoni et al, 1996,拉西地平能降低TNF-a 刺激内皮细胞粘附分子的表达,Journal of Hypertension, 1999;17:1837-1841,细胞粘附分子表达的减少 (%),氨氯地平,拉西地平,乐卡地平,0,-10,-20,-30,-40,-50,-60,-70,-80,-90,拉西地平抑制平滑肌细胞增殖和胆固醇脂化,剂型 胆固醇的 dose 增殖效果 研究 脂化作用 (mm) Lacidipine 10-6 Inhibition Mason (1992) Reduction ( 95%) 1-20 Inhibition Bernini (1993) Nifedipine Reduction Etingin, Hajjar (1985), and Schmitz (1988) Increase Daugherty (1987) No effect 10-50 Inhibition Bernini (1991, 1993) Verapamil Reduction Daugherty (1987) Reduction (91%) 50 Inhibition Bernini (1993) Diltiazem Reduction Daugherty (1987),Reichardt, 1995,拉西地平治疗52周对高血压患者 血清超氧化物歧化酶 (SOD)活性的影响,Yamakado, 1994,Before lacidipine,0,1,2,4,5,3,Serum superoxide dismutase activity (U/ml),After lacidipine,*,* p 0.05,拉西地平治疗52周对高血压患者血清过氧化物酶的影响,Yamakado, 1994,Before lacidipine,0,1,2,4,5,3,Serum lipid peroxidase (nmol/ml),After lacidipine,* p 0.05,*,6,7,短效及长效CCB对血压的影响,Optimal therapeutic range,0 4 8 12 16 20 0 4 8 12 16 20 0,mmHg,-30,-20,-10,0,Day 27 Day 28,Short-acting drug,Long-acting drug,Early morning blood pressure surge,凌晨血压增高的风险,6:00,0:00,12:00,18:00,Muller et al. N Engl J Med 1985;313:13151322 Marler et al. Stroke 1989;20:473476,0,20,40,60,80,100,120,140,160,180,脑血管事件 (per 2 h),0,5,10,15,20,25,30,35,40,45,50,心肌梗死 (per h),Stroke (n=1,167),Myocardial infarction (n=2,999),Time of day,钙离子拮抗剂的T/P值,药物 T/P 值 SBP T/P值 DBP T/P 值 平均 T/P值 硝苯地平控释片 101.8 88.2 95.0 非洛地平 75 68 71.5 氨氯地平 68 67 67.5 缓释地尔硫卓 74 67 70.5,拉西地平治疗后血压峰值和谷值的变化,Peak,Systolic blood pressure (mmHg),Diastolic blood pressure (mmHg),55% 84% 98% 78%,0 -5 -10 -15 -20 -25,Placebo 1mg 2mg 4mg 6mg,63% 79% 89% 94%,0 -5 -10 -15 -20 -25,Meredith, 1997,Lacidipine 降低了高血压患者血压变异性,SBP,DBP,Variability,mmHg,Placebo Lacidipine,15 13 11 9 7 0,15,Baseline Treatment,mmHg,Palatini et al, 1991,Baseline Treatment,13,11,9,7,0,拉西地平长期治疗后 动脉顺应性明显改善,Pancera, 1989,Baseline,Compliance (dyne-1cm410-7),3,1 month,6 months,*,* p 0.005 vs baseline,2.5,2,1.5,1,0.5,0,钙拮抗剂-二氢吡啶类 适应证 禁忌证 强制性 可能的 老年人 (无) 快速心律失常 单纯收缩期高血压 充血性心力衰竭 心绞痛 周围血管病 颈动脉粥样硬化 妊娠,2003 ESC/ESH 药物的适应证/禁忌证,Investigator assessment of lacidipine efficacy,Tcherdakoff, 1995,Very good,Good,Moderate,Bad,44%,2%,All patients,43%,46%,11%,1%,42%,Patients 65 years,11%,Investigator assessment of lacidipine tolerability,Tcherdakoff, 1995,37%,All patients,58%,38%,6%,5
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2025年个人租房合同范本下载
- 汽车零部件行业生产管理与质量控制方案
- 地理知识拓展:《地球的形成与演化》课程设计
- 社区农业技术服务中心共建协议
- 电脑设备维修服务合同
- 假如我是一只小鸟想象中的自由生活作文(15篇)
- 酒店入住与退订服务协议
- 生态学环境保护测试
- 2024届河南省郑州市高三下学期第三次质量预测文综地理试题(解析版)
- 食品营养与健康安全模拟试卷
- 外卖骑手劳务合同协议书
- T/CAMIR 002-2022企业技术创新体系建设、管理与服务要求
- DB31/T 595-2021冷库单位产品能源消耗指标
- 第五章 SPSS基本统计分析课件
- 2025年计算机Photoshop操作实务的试题及答案
- 2025时事热点政治题及参考答案(满分必刷)
- GB/T 23453-2025天然石灰石建筑板材
- 2024-2030全球WiFi 6移动热点行业调研及趋势分析报告
- 砌砖理论考试题及答案
- 中医针灸治疗脑梗塞后遗症的应用实践
- 2025年高等数学期末考试试题及答案
评论
0/150
提交评论